Healthcare / BiotechnologyTaiwan
$31.30
+0.30 (+0.97%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $336.8M · quality 65.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
52/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.0B
P/E
16.3x
↓EV/EBITDA
9.6x
↓ROE
10.6%
↑Gross Margin
43.2%
↓Debt/Equity
0.44
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+5.7%
FCF CAGR
+12.2%
FCF margin
11.4%
FCF / Net income
1.05x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.37B · net income $365.8M · FCF $383.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.37B | $3.37B | $3.15B | $2.96B | $2.86B |
| Net Income | $365.8M | $365.8M | $304.7M | $375.2M | $224.6M |
| EBITDA | $689.7M | $689.7M | $601.2M | $582.9M | $539.6M |
| EPS | — | — | 1.68 | 1.97 | 1.24 |
| Gross Margin | 43.2% | 43.2% | 39.3% | 36.8% | 38.2% |
| Operating Margin | 12.4% | 12.4% | 9.3% | 9.7% | 6.9% |
| Net Margin | 10.8% | 10.8% | 9.7% | 12.7% | 7.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.44 | 0.44 | 0.58 | 0.63 | 0.65 |
| Current Ratio | 2.50 | 2.50 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $383.7M | $383.7M | $336.8M | $-4.6M | $271.9M |
| Returns | |||||
| ROE | 10.6% | 10.6% | 9.3% | 12.1% | 7.7% |
| Valuation | |||||
| P/E | 16.30 | 16.30 | 17.63 | 15.16 | 22.64 |
| EV/EBITDA | 9.57 | 9.57 | 10.76 | 11.26 | 11.17 |
| P/B | 1.73 | 1.73 | 1.73 | 1.84 | 1.83 |
| Growth & Yield | |||||
| Revenue Growth | 7.0% | 7.0% | 6.3% | 3.7% | — |
| EPS Growth | — | — | -14.8% | 58.9% | — |
| Dividend Yield | 3.1% | 3.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+1.2%
Start / end P/E
n/dx → n/dx
EPS bridge
1.68 → n/d
Residual
-1.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.